Authors: Nazeli Zaqaryan1 Rita Khallouf, Arpi Manukyan, Vahe Atoyan, Astghik Tsokolakyan, Mkrtich A. Yeranosyan, Samvel G. Chailyan and Kristine E. Danielyan
Citation: The Open Biotechnology Journal • 14 July 2025 • RESEARCH ARTICLE
DOI: 10.2174/0118740707379038250617195726
Summary: The main take-away messages from this study are that stable, layered PEG/albumin nanoparticles (NPs) were successfully synthesized for use as drug carriers in the treatment of experimental stroke. These drug-loaded carriers demonstrated high stability and prolonged circulation in the bloodstream, with a half-life (T1/2) ranging from 7.64 to 13 days. Importantly, both albumin particles and PEGylated albumin carriers loaded with dexamethasone and allopurinol significantly preserved the integrity of the blood–brain barrier (BBB) in experimental oxidative brain damage, suggesting their potential for targeting various stages of stroke recovery.
